Sotagliflozin for kidney protection in type 1 diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had type 1 diabetes for at least 8 years and are on insulin therapy.
- Your kidney function (eGFR) is between 20 and 60, and you have protein in your urine (UACR ≥200 mg/g or ≥100 mg/g with a history of protein).
- Your blood pressure is 155/95 or lower, and you are taking standard medications for kidney protection (like ACE inhibitors or ARBs).
- You have not taken an SGLT2 inhibitor (like empagliflozin or dapagliflozin) in the last 2 months, and you are not on certain other glucose-lowering medications unless stable.
- You are willing to wear a continuous glucose monitor (CGM) for the entire study and attend all study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called an SGLT2 inhibitor (canagliflozin-like) can help slow kidney disease in people with type 1 diabetes. It may help protect your kidneys if you already have protein in your urine and reduced kidney function.
This trial tests a medication called sotagliflozin for people who have both type 1 diabetes and heart failure symptoms. The goal is to see if it can improve how you feel and manage your heart and diabetes.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
This study tests if ganagliflozin, a once-daily pill, can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and manage blood sugar.
Hear when a new Diabetic Nephropathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.